Neal v. Smithkline Beecham Corporation

Full title: TERRI S. O'NEAL, individually and as successor-in-interest to the Estate…

Court: United States District Court, E.D. California, Sacramento Division

Date published: Jan 18, 2008

Case No.: 2:06-CV-01063-FCD-DAD (E.D. Cal. Jan. 18, 2008)

Opinion

Case No.: 2:06-CV-01063-FCD-DAD.

January 18, 2008

ORDER GRANTING DEFENDANT SMITHKLINE BEECHAM CORPORATION, D/B/A GLAXOSMITHKLINE'S REQUEST FOR CERTAIN EXHIBITS FILED BY PLAINTIFFS IN OPPOSITION TO GSK'S MOTION FOR SUMMARY JUDGMENT (FEDERAL PREEMPTION) TO BE SEALED

FRANK DAMRELL JR., District Judge

Defendant SmithKline Beecham Corporation, d/b/a GlaxoSmithKline ("GSK"), by counsel, having filed its Response to Plaintiffs' Ex Parte Application to Conditionally File Under Seal Documents and Exhibits in Support of Plaintiffs' Opposition to GSK's Motion for Summary Judgment (Federal Preemption), as certain exhibits filed by Plaintiffs contain sensitive and confidential commercial information, research, development information, and trade secrets regarding Paxil, and the Court, being duly advised, now finds that exhibits 2 (pages 410, 417-420, 431 (lines 6-24), 464-466, 468 (line 25) — 469); 3 (pages 161-165, 169); 4 (pages 168-170, 184-186); 5 (pages 126 (lines 4-11, 18-24), 149 (lines 2-23), 165-166, 169-171, 174, 219 (lines 14-24)); 6, 8 (pages 47 (line 1) — 48 (line 7), 109 (line 12) — 116 (line 11), 164 (line 19) — 167 (line 15), 193 (lines 8-11), 195 (lines 17-23), 210 (lines 10-14), 218 (line 4) — 219 (line 10), 221 (line 9) — 222 (line 10), 223 (line 8) — 224 (line 17), 241 (line 13) — 242 (line 10), 243 (line 14) — 244 (line 12), 256 (line 20) — 259 (line 1), 263 (line 14) — 267 (line 2); 273 (line 1) — 274 (line 20), 275 (line 8) — 278 (line 23), 286 (line 17) — 287 (line 12), 321 (line 17) — 322 (line 2), 322 (lines 5-20), 325 (lines 18-24), 327 (line 17) — 329 (line 9), 330 (lines 2-6), 331 (lines 9-14)); 9 (pages 70 (line 24) — 71 (line 7), 90 (lines 4-17), 99 (lines 2-14), 100 (line 22) — 101 (line 2)); 10 (pages 165, 249 (lines 6-9); 11 (pages 62 (line 21) — 63 (line 9), 123 (line 20) — 124 (line 13), 126 (line 14) — 127 (line 3), 128 (lines 22-24)); 16-18; 19 (pages 122 (lines 21-23), 123 (lines 1-2), 127 (line 13) — 128 (line 1), 128 (lines 14-17), 131 (lines 8-14)); 21-25; 26 (only PAR008964009 within exhibit); 28; 31; 40; 42-43; 59; 63; and 65 to the Declaration of George W. Murgatroyd III; exhibits 1 (previously sealed pages 4-7, 9-13), and 2 (previously sealed in entirety) to the Declaration of Joseph Glenmullen, M.D.; and exhibit 1 to the Declaration of Roger Grimson, Ph.D, shall be SEALED.

IT IS SO ORDERED.